Purpose LUME-Meso is a phase II/III randomized, double-blind trial designed to assess
efficacy and safety of nintedanib plus chemotherapy as first-line treatment of malignant …

PURPOSE Antiangiogenic agents combined with chemotherapy have efficacy in the
treatment of unresectable malignant pleural mesothelioma (MPM). Cediranib (AstraZeneca …

Systemic chemotherapy with pemetrexed and cisplatin has been the cornerstone of
treatment for advanced pleural mesothelioma since 2004, when the EMPHACIS trial …

7081 Background: Cisplatin is one of the most active drugs available in MPM while
bortezomib has shown some activity in single agent phase II studies against MPM. This was …

Malignant pleural mesothelioma (MPM) is a rare, aggressive neoplasm that is usually
diagnosed at an advanced stage with an unfavorable prognosis. 1, 2 Eighty percent of cases …

Background We report the results of a single-arm, prospective, non-randomized, non-
comparative, open label, multicenter, phase II trial designed to assess the activity and safety …

Background Pemetrexed in combination with cisplatin (Pem/Cis) is the only approved
chemotherapeutic regimen for malignant pleural mesothelioma (MPM). At the time of launch …

BACKGROUND. We conducted a phase 2, multicenter, open‐label study of erlotinib plus
bevacizumab in patients with malignant pleural mesothelioma who had previously received …

Methods PEMMELA was a prospective single-center, single-arm, open-label, investigator-
initiated phase 2 trial of pembrolizumab (200 mg once every three weeks intravenously) plus …

Background We aimed to evaluate the efficiency and safety of cis/carboplatin plus
gemcitabine, which was previously used for mesothelioma but with no recorded proof of its …